Latest news with #LANT
Los Angeles Times
23-03-2025
- Health
- Los Angeles Times
Physicist Dr. Hadiyah-Nicole Green Uses Nonprofit to Raise Funds for Cancer-Killing Technology
In 2003, Dr. Hadiyah-Nicole Green graduated with a B.S. in Physics from Alabama A&M University with a plan to revolutionize the way consumers receive cable TV and internet. She had diligently prepared herself for her future career in fiber optics and optical communication, and she was excited to finally be on her way. The day after graduation, Dr. Green's aunt, who had raised her along with her two older brothers, disclosed that she had cancer. 'She told us she had 'woman's cancer,' which usually means cervical or ovarian cancer, and was only given three months to live,' Dr. Green recalled. 'She also said she'd rather die than experience the side effects of chemo or radiation treatments.' As Dr. Green nursed her aunt through the ravages of the disease, she remembers thinking, 'We have satellites in outer space that can tell whether a dime on the ground is face up or face down, but we can't treat a tumor just at the site of the tumor? That doesn't make sense.' Three months after her aunt died, Dr. Green's uncle, her late aunt's husband, was diagnosed with esophageal cancer and given up to six months to live. Dr. Green was the primary caregiver for her uncle while he received the conventional treatments of radiation and chemo. Although with treatment, Dr. Green's help, and God's grace, her uncle lived 10 years past his original prognosis, Dr. Green saw his body bear the brunt of the treatment's brutal side effects. 'I watched him wither down to nothing after losing 150 pounds,' Dr. Green said. 'He lost all of his hair on his head, his eyebrows, and his eyelashes, and his skin looked like it had been barbequed.' Seeing her aunt and uncle suffer at the hands of cancer and cancer treatments inspired Dr. Green to dedicate her life to developing innovative and more humane ways to attack and destroy cancer. In 2005, she enrolled in the physics Ph.D. program at the University of Alabama in Birmingham (UAB) to develop this inspired cancer treatment using lasers and nanotechnology. A cure without sufferingCancer has impacted most of us. While cancer that is detected early has a high cure rate, nearly 10 million people still die from cancer each year worldwide. Even with the best care, any of us – our family, friends, or colleagues – can be subjected to ineffective treatments, harsh side effects, lengthy treatment durations, prohibitive costs, and limited accessibility. Now, there's a better way! Dr. Green developed a novel cancer-killing technology, Laser-Activated NanoTherapy (LANT), that is of high clinical relevance in the field of oncology. LANT directly addresses the urgent yet unmet global need for more effective treatment options for millions of people with difficult-to-treat cancers. LANT is designed as a minimally invasive, curative treatment for solid tumors that induces site-specific (not cell type-specific) cellular death and tumor regression precisely at the site of laser activation. The peer-reviewed, preclinical in vivo LANT data showed complete tumor regression with clear tumor margins and healed skin in just 15 days after a single, 10-minute treatment without surgery, chemotherapy, radiation or observed side effects. Because its mechanism of action is based on physics instead of biology, LANT is a platform therapy designed to have clinical indications for a variety of difficult-to-treat solid tumors, such as brain, pancreatic, breast, prostate, and head and neck cancers. Dr. Green founded the Ora Lee Smith Cancer Research Foundation, a cancer nonprofit, to keep the technology she developed affordable for all. The Ora Lee Smith Cancer Research Foundation is on a mission to change the way cancer is treated and reduce cancer patient suffering by providing a treatment that is accessible, affordable and effective. Limited by funding, not technological advancements, the Ora Lee Foundation is ready to move LANT beyond the laboratory and into humans with tax-deductible donations. When you support the Ora Lee Smith Cancer Research Foundation, your donations will help ensure Dr. Green's research comes to life by helping to fund human clinical trials, taking this tech from the lab to the living. The future of cancer researchDr. Green acknowledges that none of us are islands; we all stand on the shoulders of those who came before us. As such, she pays it forward by creating opportunities in her research laboratory and nonprofit for women and students in STEM to grow their research and personal skills. She also advises her mentees and trainees on educational, career, and life strategies. 'My advice to young women interested in pursuing research careers would be to excel in your coursework and obtain summer and work-study research experiences to help confirm or narrow your scientific interests,' Dr. Green said. 'Put your best into everything that you do, so that when opportunities come, you will be prepared. Everyone has a divine purpose for being on the planet. Channel your joy or pain and the things that make you happy or angry, into your purpose or to help you identify your purpose.' Dr. Green says, 'I turned my pain into passion and used the loss of my loved ones to cancer to develop new ways to fight cancer. I also channeled the skills I built as the president of different organizations in college into my position as the founder of my nonprofit.' If you haven't found your purpose, Dr. Green recommends supporting something or someone you believe in, and by dedicating time and effort to something bigger than yourself, you will gain experience and skills that may be the investment needed to achieve your own success. Explore Your Future in Healthcare – Learn More Now
Yahoo
12-03-2025
- Business
- Yahoo
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1st, 2025. She will serve on Ipsen's Executive Leadership Team (ELT) and report directly to Chief Executive Officer David Loew. In this newly created role, she will lead Ipsen's global neurotoxins franchise, overseeing strategy and execution across both therapeutic and aesthetic indications. Over the last 30 years in the neurotoxins market, Ipsen has established itself as one of the leading players in neurosciences, successfully driving research, clinical development and growth based on significant manufacturing know-how and capacity. "We are delighted to welcome Olivia to Ipsen's Executive Leadership Team. With her deep expertise in neurotoxins, combined with her experience in global strategy and commercialization, she will be instrumental in further accelerating our growth and innovation in neurotoxins, both in the therapeutic and aesthetic space," said David Loew, CEO, Ipsen. 'With a robust portfolio of products and an attractive pipeline including the potential break-through innovation of the recombinant Long-Acting Neuro-Toxine (LANT) program, it is the right time for us to create an integrated franchise. The long acting neurotoxin was uniquely designed to bind to the receptors used by the BoNT B and to deliver the active light chain of the BoNT A, demonstrating in preclinical studies a longer duration of action and less tissue spread compared to currently available BoNT As. We believe LANT AB has the potential ability to deliver better outcomes for patients with an increased duration of action, leading to a potential reduction in injection frequency and enhanced tolerability.' Olivia brings over 20 years of global leadership experience in pharmaceuticals and medical aesthetics, with a strong track record in business transformation, market expansion, and product launches. Most recently, she was at Novartis, where she led the establishment of a new therapeutic area in Allergy & Immunology. Previously, she held senior leadership positions at Merz Aesthetics and Galderma, where she played a key role in expanding the global neurotoxins market."I am excited to join Ipsen at such an important time for its neurotoxins business. Ipsen has a strong foundation in innovation, and I look forward to working with the team to build on this success and drive further growth in this dynamic market,' said Olivia Brown. This appointment reflects Ipsen's continued investment in neurotoxin innovation, global expansion, and leadership in both therapeutic and aesthetic indications. * botulinum toxin type B (BoNT-B) ** botulinum toxin type A (BoNT-A) About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit Ipsen contacts Investors Alina LEVCHUK | + 41 79 572 8712 | Nicolas BOGLER | + 33 6 52 19 98 92 | Media Sally BAIN | + 1 857 320 0517 | Anne LIONTAS | + 33 7 67 34 72 96 | Disclaimers and/or Forward-Looking StatementsThe forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment PR_ELT Announcement_13032025Sign in to access your portfolio
